Abstract:Peritoneal carcinomatosis (PC) is usually caused by widespread cancer metastatic cells within the peritoneal cavity and occurred in 85% of ovarian cancer patients and 5-20% of colorectal carcinoma patients. Because of the poverty of symptoms, patients are diagnosed with an advanced stage. PC will be the leading death cause of these patients. Recently, the treatment was limited to standard palliative surgery and intravenous chemotherapy with very poor results in term of survival. The development of new surgical techniques combined with intraperitoneal chemotherapy associated or not with hyperthermia provided new hope of a potential cure for patients with PC. Indeed, complete cytoreductive surgery represents the most important prognostic factor for patients with PC whatever the primary cancer locations. Combined treatment using complete cytoreductive surgery and intraperitoneal chemotherapy has been developed leading to unprecedented survival. Hyperthermia induces a selective destruction of tumor cells in hypoxic and acidic parts of tumors, but leaves normal tissues intact. In addition heat is acting for synergy with the cytotoxic agent. A new technique to deliver intraoperative intraperitoneal chemotherapy associated with hyperthermia, called HIPEC, was developed for patient with PC. It significantly increases survival in patients with colic cancer PC, peritoneal mesothelioma and pseudomyxoma peritonei. Several ongoing trails have been designed to establish the real role of HIPEC for different pathology. First, because of the major development and the widespread use of minimal invasive surgery, recruitment of patients has been profoundly changed with localized PC. We have demonstrated in an experimental study the feasibility and reliability of laparoscopic peritonectomy followed by oxaliplatin based intraperitoneal chemotherapy and its pharmacokinetics consequences regarding the peritoneal drug absorption, the increased tissue diffusion, and the role of intraperitoneal pressure. Several articles were published in Gynecologic Oncology and in Annals of Surgical Oncology and in an international book chapter (Humana Press) concerning pharmacology and pharmacokinetics of platinum salts. Then, to establish a new population pharmacokinetic model and to compare two procedures of drug's delivery during HIPEC, data from 24 patients treated with oxaliplatin based HIPEC were collected and analyzed. This work was published in Cancer Chemotherapy and Pharmacology. Finally, different clinical and pharmacodynamic studies were performed to evaluate the toxicity for patients who underwent complete cytoreductive surgery associated to Cisplatin or Oxaliplatin based HIPEC. Three different works were performed to evaluate the renal toxicity of cisplatin based HIPEC. An unpublished PK study regarding acute renal failure in a dose-deescalation study was presented at a Pharmaco-oncologists Meeting. The results were confirmed in a bicentric retrospective study highlighting some risk factors (Submitted to the European Journal of Surgical Oncology). Finally, a phase I study dose escalation of hyperthermic intraperitoneal cisplatin was conducted with the establishment of the recommended dose of cisplatin for HIPEC (Submitted to the Journal of Clinical Oncology). Because of renal toxicity related to cisplatin based HIPEC, a phase II prospective study was conducted to evaluate the morbidity of oxaliplatin based HIPEC. As a result of this high morbidity rate (hemoperitoneum), this trial was prematurely closed and published in the European Journal of Surgical Oncology. Finally, to evaluate the relationship between oxaliplatin exposure and observed toxicity, a population pharmacokinetics was conducted in 75 patients treated with CRS and oxaliplatin based HIPEC. A PK contribution, relative to the absorption phenomenon, on the severity of the thrombocytopenia and hemoperitoneum was shown. This work was published in Cancer Chemotherapy and Pharmacology

Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols

Rationale for Heating Oxaliplatin for the Intraperitoneal Treatment of Peritoneal Carcinomatosis: A Study of the Effect of Heat on Intraperitoneal Oxaliplatin Using a Murine Model

Therapeutic methods for peritoneal carcinomatosis : standardization of hyperthermic intraperitoneal chemotherapy pharmacokinetics and pharmacodynamic studies

A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers

PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy

Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.

The metabolic fate of oxaliplatin in the biological milieu investigated during in vivo lung perfusion using a unique miniaturized sampling approach based on solid-phase microextraction coupled with liquid chromatography-mass spectrometry

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform

Intraperitoneal Chemohyperthermia (ipch) with Oxaliplatin for Patients with Colorectal Peritoneal Carcinomatosis.

Systemic Evaluation on the Pharmacokinetics of Platinum-Based Anticancer Drugs From Animal to Cell Level: Based on Total Platinum and Intact Drugs

Pharmacokinetics of Cisplatin in the Systemic versus Hyperthermic Intrathoracic or Intraperitoneal Chemotherapy

Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases

Introducing Hyperthermic Intraperitoneal Chemotherapy into Gynecological Oncology Practice - Feasibility and Safety Considerations: Single-Center Experience

Abstract 2825: Experimental hyperthermic intraperitoneal chemotherapy in mice: Establishment of a novel ovarian cancer xenograft model

Postoperative Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy: an Effective and Safe Palliative Treatment Option for Colorectal Cancer with Peritoneal Metastasis

Clinical Study of Intraperitoneal Chemohyperthermia(IPCH) with Oxaliplatin for Patients with Peritoneal Carcinomatosis of Colorectal Cancer

Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases